Multifocal hepatoblastoma: Is there a place for partial hepatectomy?
Corresponding Author
Patrizia Dall'Igna MD
Department of Pediatrics, Division of Pediatric Surgery, University-Hospital of Padua, Italy
Division of Pediatric Surgery, Department of Pediatrics, University-Hospital of Padua, Via Giustiniani 3, 35128 Padua, Italy.Search for more papers by this authorGiovanni Cecchetto MD
Department of Pediatrics, Division of Pediatric Surgery, University-Hospital of Padua, Italy
Search for more papers by this authorTiziana Toffolutti MD
Department of Pediatrics, Division of Radiology, University-Hospital of Padua, Italy
Search for more papers by this authorUmberto Cillo MD
Division of General Surgery, Hepatic Liver Transplantation Program, University-Hospital of Padua, Italy
Search for more papers by this authorAttilio Cecchetto MD
Institute of Pathology, University-Hospital of Padua, Italy
Search for more papers by this authorMaurizio Guglielmi MD
Department of Pediatrics, Division of Pediatric Surgery, University-Hospital of Padua, Italy
Search for more papers by this authorGiorgio Perilongo MD
Department of Pediatrics, Division of Hematology-Oncology, University-Hospital of Padua, Italy
Search for more papers by this authorJack Plaschkes MD
Childhood Liver Tumour Strategy Group of SIOP, University Children's Hospital, Department of Pediatric Surgery, Berne, Switzerland
Jack Plaschkes is working as a Chairman of the Childhood Liver Tumour Strategy Group of SIOP, University Children's Hospital, Department of Pediatric Surgery, CH-3010 Berne, Switzerland.
Search for more papers by this authorCorresponding Author
Patrizia Dall'Igna MD
Department of Pediatrics, Division of Pediatric Surgery, University-Hospital of Padua, Italy
Division of Pediatric Surgery, Department of Pediatrics, University-Hospital of Padua, Via Giustiniani 3, 35128 Padua, Italy.Search for more papers by this authorGiovanni Cecchetto MD
Department of Pediatrics, Division of Pediatric Surgery, University-Hospital of Padua, Italy
Search for more papers by this authorTiziana Toffolutti MD
Department of Pediatrics, Division of Radiology, University-Hospital of Padua, Italy
Search for more papers by this authorUmberto Cillo MD
Division of General Surgery, Hepatic Liver Transplantation Program, University-Hospital of Padua, Italy
Search for more papers by this authorAttilio Cecchetto MD
Institute of Pathology, University-Hospital of Padua, Italy
Search for more papers by this authorMaurizio Guglielmi MD
Department of Pediatrics, Division of Pediatric Surgery, University-Hospital of Padua, Italy
Search for more papers by this authorGiorgio Perilongo MD
Department of Pediatrics, Division of Hematology-Oncology, University-Hospital of Padua, Italy
Search for more papers by this authorJack Plaschkes MD
Childhood Liver Tumour Strategy Group of SIOP, University Children's Hospital, Department of Pediatric Surgery, Berne, Switzerland
Jack Plaschkes is working as a Chairman of the Childhood Liver Tumour Strategy Group of SIOP, University Children's Hospital, Department of Pediatric Surgery, CH-3010 Berne, Switzerland.
Search for more papers by this author
REFERENCES
- 1 Von Schweinitz D, Hecker H, Harms D, et al. Complete resection before development of drug resistance is essential for survival from advanced hepatoblastoma. A report from the German Cooperative Pediatric Liver tumour Study HB-89. J Pediatr Surg 1995; 30: 845–852.
- 2 Pritchard J, Brown J, Shafford E, et al. Cisplatin, doxorubicin and delayed surgery for childhood hepatoblastoma: a successful approach. Results of the first prospective study of the International Society of Pediatric Oncology. J Clin Oncol 2000; 15: 3819–3828.
- 3 Ortega JA, Krailo MD, Haans JE, et al. Effective treatment of unresectable or metastatic hepatoblastoma with cisplatin and doxorubicin chemotherapy. J Clin Oncol 1991; 9: 2167–2176.
- 4 Douglass EC, Finegold M, Reynolds M, et al. Cisplatin, vincristine and fluorouracil therapy for hepatoblastoma: a Pediatric Oncology Group Study. J Clin Oncol 1993; 11: 96–99.
- 5 Ortega JA, Douglass EC, Feusner JH, et al. Randomized comparison of cisplatin/vincristine/fluorouracil and cisplatin/continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: a report from the Children's Cancer Group and the Pediatric Oncology Group. J Clin Oncol 2000; 18: 2665–2675.
- 6 Brugieres L, Plaschkes J, MacKinley G, et al. Hepatoblastoma-microscopical residual disease after delayed surgery: prognostic implications. Med Pediatr Oncol 2000; 35: 177.
- 7 Von Schweinitz D, Wischmeyer P, Leuschnere I, et al. Clinico-pathological criteria with prognostic relevance in hepatoblastoma. Eur J Cancer 1994; 30A: 1052–1058.
- 8 Brown J, Perilongo G, Shafford E, et al. Pretreatment prognostic factors for children with hepatoblastoma—results from the International Society of Paediatric Oncology (SIOP) study SIOPEL 1. Eur J Cancer 2000; 36: 1418–1425.
- 9 Stone RD, Beasley PJ, Treacy SJ. Children and families can achieve normal psychological adjustment and good quality of life following pediatric liver transplantation: a long-term study. Transplant Proc 1997; 29: 1571–1572.
- 10 Goss JA, Shackleton CR, Mc Diarmid SV, et al. Long-term results of pediatric liver transplantation. An analysis of 569 transplants. Ann Surg 1998; 228: 411–420.
- 11 Mazariegos GV, Reyes J, Marino IR, et al. Weaning of immunosuppression in liver transplant recipients. Transplantation 1997; 63: 243–249.
- 12 Mazariegos GV, Reyes J, Marino IR, et al. Risks and benefits of weaning immunosuppression in liver transplant recipients: long-term follow-up. Transplant Proc 1997; 29: 1174–1177.
